|
시장보고서
상품코드
2055077
임상 유전체학 시장 : 제품 및 서비스별Clinical Genomics Market, By Product and Service (Instruments or Systems, and Consumables, By Technology, By Application (Oncology, Infectious Diseases, By End User, By Geography )) |
||||||
임상 유전체학 시장은 2026년에 139억 3,000만 달러로 추정되며, 2033년까지 296억 5,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 11.4%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 139억 3,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 11.40% | 2033년 시장 규모 예측 : | 296억 5,000만 달러 |
세계 임상 유전체학 시장은 헬스케어 업계에서 급속히 발전하고 있는 분야로, 맞춤형 의료 및 정밀의료의 양상을 근본적으로 변화시키고 있습니다. 임상 유전체학이란 의료적 의사 결정, 질환 진단, 치료법 선택 및 예후 판정에 활용하기 위해 개인의 유전적 구성을 종합적으로 분석하는 분야입니다. 이 학제적 분야는 유전체 연구와 임상 실무 간의 격차를 해소하여, 의료진이 환자의 고유한 유전자 프로파일에 기반하여 맞춤형 의료 개입을 제공할 수 있도록 합니다.
이 시장은 전장 유전체 시퀀싱, 표적 유전자 패널, 약물유전체학 검사, 종양 유전체학, 희귀질환 진단 등 광범위한 기술, 서비스 및 응용 분야를 아우르고 있습니다. 전 세계 의료 시스템이 정밀 의학 접근 방식을 점점 더 많이 도입함에 따라, 임상 유전체학은 신약 개발, 바이오마커 발견 및 치료법 최적화 분야의 혁신을 주도하는 기반 기술로 부상하고 있습니다. 첨단 시퀀싱 기술, 인공지능, 빅데이터 분석의 통합을 통해 유전체 검사의 접근성, 정확도, 비용 대비 효과가 크게 향상되어, 전 세계의 다양한 의료 현장과 환자 집단에서 일상적인 임상 도입이 더욱 현실화되고 있습니다.
시장 역학
세계 임상 유전체학 시장은 성장세를 지속적으로 가속화하고 있는 몇 가지 강력한 시장 성장 촉진요인에 힘입어 성장하고 있습니다. 전 세계적으로 유전성 질환, 암, 희귀질환의 유병률이 증가함에 따라 정밀한 진단 및 치료 솔루션에 대한 수요가 크게 높아지고 있으며, 임상 유전체학은 의료 종사자들에게 없어서는 안 될 도구로서의 입지를 확고히 하고 있습니다. 차세대 염기서열 분석(NGS) 기술의 발전, 유전체 검사 비용의 감소, 그리고 데이터 분석 능력의 향상으로 인해 유전체 분석이 더욱 이용하기 쉬워졌으며, 임상 현장에서의 광범위한 도입이 현실화되었습니다. 국가 유전체 프로젝트와 정밀의료 프로그램을 포함한 유전체 연구에 대한 정부의 이니셔티브와 막대한 투자가 시장 확대에 큰 탄력을 주고 있습니다.
의료 종사자와 환자들 사이에서 맞춤형 의료의 이점에 대한 인식이 높아지고 있는 데다, 전 세계 의료비 증가가 시장 성장을 더욱 촉진하고 있습니다. 그러나 시장은 지역마다 다른 복잡한 규제 체계 등 뚜렷한 제약에 직면해 있어, 시장 진출기업들에게 규정 준수상의 과제가 되고 있습니다. 초기 인프라 비용의 높음, 숙련된 유전체 전문가의 부족, 그리고 데이터의 개인정보 보호 및 보안에 대한 우려는 특히 개발도상국에서 시장 침투의 큰 장벽이 되고 있습니다. 유전자 검사와 관련된 윤리적 고려 사항과 잠재적인 차별 문제 또한 시장의 확산을 제한하고 있습니다. 그럼에도 불구하고, 약물 선택 및 투여 전략의 최적화를 가능하게 하는 약물유전체학 분야의 응용 확대와, 데이터 분석 및 해석의 고도화를 위한 인공지능(AI) 및 머신러닝 기술의 통합이 진행되고 있어, 큰 기회가 존재합니다. 신흥 시장에는 아직 개척되지 않은 성장 잠재력이 있으며, 한편 포인트 오브 케어(PoC) 유전체 검사 및 체액 생검 기술 분야의 지속적인 혁신은 시장 확대와 환자 예후 개선을 위한 유망한 길을 제시하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 임상 유전체학 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 임상 유전체학 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 임상 유전체학 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 임상 유전체학 시장 : 제품 및 서비스별, 2021년-2033년
제5장 세계의 임상 유전체학 시장 : 기술별, 2021년-2033년
제6장 세계의 임상 유전체학 시장 : 용도별, 2021년-2033년
제7장 세계의 임상 유전체학 시장 : 최종사용자별, 2021년-2033년
제8장 세계의 임상 유전체학 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌 및 조사 방법
LSH 26.06.22Clinical Genomics Market is estimated to be valued at USD 13.93 Bn in 2026 and is expected to reach USD 29.65 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 13.93 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.40% | 2033 Value Projection: | USD 29.65 Bn |
The Global Clinical Genomics Market represents a rapidly evolving sector within the healthcare industry, fundamentally transforming the landscape of personalized medicine and precision therapeutics. Clinical genomics encompasses the comprehensive analysis of an individual's genetic makeup to inform medical decision-making, disease diagnosis, treatment selection, and prognosis determination. This interdisciplinary field bridges the gap between genomic research and clinical practice, enabling healthcare providers to deliver tailored medical interventions based on patients' unique genetic profiles.
The market encompasses a broad spectrum of technologies, services, and applications including whole genome sequencing, targeted gene panels, pharmacogenomics testing, oncology genomics, and rare disease diagnostics. As healthcare systems worldwide increasingly adopt precision medicine approaches, clinical genomics has emerged as a cornerstone technology driving innovation in drug development, biomarker discovery, and therapeutic optimization. The integration of advanced sequencing technologies, artificial intelligence, and big data analytics has significantly enhanced the accessibility, accuracy, and cost-effectiveness of genomic testing, making it more viable for routine clinical implementation across diverse healthcare settings and patient populations globally.
Market Dynamics
The Global Clinical Genomics Market is propelled by several compelling drivers that continue to accelerate its growth trajectory. The increasing prevalence of genetic disorders, cancer, and rare diseases worldwide has created substantial demand for precise diagnostic and therapeutic solutions, positioning clinical genomics as an indispensable tool for healthcare providers. Technological advancements in next-generation sequencing (NGS), declining costs of genomic testing, and improved data interpretation capabilities have made genomic analysis more accessible and practical for widespread clinical adoption. Government initiatives and substantial investments in genomics research, including national genome projects and precision medicine programs, have provided significant momentum to market expansion.
The growing awareness among healthcare professionals and patients about the benefits of personalized medicine, coupled with increasing healthcare expenditure globally, further drives market growth. However, the market faces notable restraints including complex regulatory frameworks that vary across different regions, creating compliance challenges for market participants. High initial infrastructure costs, shortage of skilled genomics professionals, and concerns regarding data privacy and security pose significant barriers to market penetration, particularly in developing economies. Ethical considerations surrounding genetic testing and potential discrimination issues also limit market adoption. Nevertheless, substantial opportunities exist through expanding applications in pharmacogenomics, which enables optimized drug selection and dosing strategies, and the growing integration of artificial intelligence and machine learning technologies for enhanced data analysis and interpretation. Emerging markets present untapped potential for growth, while continuous innovation in point-of-care genomic testing and liquid biopsy technologies offers promising avenues for market expansion and improved patient outcomes.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global clinical genomics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Illumina Inc, Thermo Fisher Scientific Inc, F Hoffmann-La Roche Ltd, QIAGEN NV, Agilent Technologies Inc, BGI Genomics, PerkinElmer Inc, Bio-Rad Laboratories Inc, Danaher Corporation (Cepheid, IDT), Oxford Nanopore Technologies, Pacific Biosciences, Myriad Genetics Inc, Guardant Health, Eurofins Scientific, and GE HealthCare.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global clinical genomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clinical genomics market.
Market Segmentation
- Product and Service Insights (Revenue, USD Bn, 2021 - 2033)
- Instruments or Systems
- Sequencers
- PCR Systems
- Microarray Scanners
- Automated Liquid Handlers
- Other Genomic Analyzers
- Consumables
- Reagents and Kits
- Sequencing Chips and Flow Cells
- Sample Collection Kits
- Others (Probes and Primers)
- Software and Services
- Data Analysis and Interpretation
- Sequencing Services
- Others (Clinical Laboratory Services, etc)
- Technology Insights (Revenue, USD Bn, 2021 - 2033)
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Microarray
- Sanger Sequencing
- Other Technologies (e.g., FISH, Karyotyping)
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Oncology
- Cancer Diagnosis and Prognosis
- Therapy Selection and Companion Diagnostics
- Hereditary Cancer Risk Assessment
- Minimal Residual Disease (MRD) Monitoring
- Liquid Biopsy Analysis
- Infectious Diseases
- Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
- Outbreak Surveillance and Strain Typing
- Antimicrobial Resistance Testing
- Genetic Disorders
- Newborn Screening
- Carrier Screening
- Prenatal Diagnosis
- Preimplantation Genetic Testing
- Diagnosis of Rare and Inherited Diseases
- Cardiovascular Diseases
- Inherited Cardiomyopathies Testing
- Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
- Aortopathies Genetic Testing (e.g., Marfan Syndrome)
- Genetic Hypercholesterolemias Testing
- Neurological Disorders
- Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
- Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
- Epilepsy Genetic Testing
- Neurodevelopmental Disorder Testing
- Other Applications (Pharmacogenomics, etc.)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Clinics
- Diagnostic Laboratories
- Pharmaceutical and Biotechnology Companies
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Player Insights (Revenue, USD Bn, 2021 - 2033)
- Illumina Inc
- Thermo Fisher Scientific Inc
- F Hoffmann-La Roche Ltd
- QIAGEN NV
- Agilent Technologies Inc
- BGI Genomics
- PerkinElmer Inc
- Bio-Rad Laboratories Inc
- Danaher Corporation (Cepheid, IDT)
- Oxford Nanopore Technologies
- Pacific Biosciences
- Myriad Genetics Inc
- Guardant Health
- Eurofins Scientific
- GE HealthCare
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Clinical Genomics Market, By Product and Service
- Global Clinical Genomics Market, By Technology
- Global Clinical Genomics Market, By Application
- Global Clinical Genomics Market, By End User
- Global Clinical Genomics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Clinical Genomics Market, By Product and Service, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Instruments or Systems
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sequencers
- PCR Systems
- Microarray Scanners
- Automated Liquid Handlers
- Other Genomic Analyzers
- Sequencers
- Consumables
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Reagents and Kits
- Sequencing Chips and Flow Cells
- Sample Collection Kits
- Others (Probes and Primers)
- Reagents and Kits
- Software and Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Data Analysis and Interpretation
- Sequencing Services
- Others (Clinical Laboratory Services, etc.)
- Data Analysis and Interpretation
5. Global Clinical Genomics Market, By Technology, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Next-Generation Sequencing (NGS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Polymerase Chain Reaction (PCR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Microarray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sanger Sequencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Technologies (e.g., FISH, Karyotyping)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Clinical Genomics Market, By Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cancer Diagnosis and Prognosis
- Therapy Selection and Companion Diagnostics
- Hereditary Cancer Risk Assessment
- Minimal Residual Disease (MRD) Monitoring
- Liquid Biopsy Analysis
- Cancer Diagnosis and Prognosis
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
- Outbreak Surveillance and Strain Typing
- Antimicrobial Resistance Testing
- Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
- Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Newborn Screening
- Carrier Screening
- Prenatal Diagnosis
- Preimplantation Genetic Testing
- Diagnosis of Rare and Inherited Diseases
- Newborn Screening
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Inherited Cardiomyopathies Testing
- Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
- Aortopathies Genetic Testing (e.g., Marfan Syndrome)
- Genetic Hypercholesterolemia's Testing
- Inherited Cardiomyopathies Testing
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
- Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
- Epilepsy Genetic Testing
- Neurodevelopmental Disorder Testing
- Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
- Other Applications (Pharmacogenomics, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Clinical Genomics Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pharmaceutical and Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Clinical Genomics Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026,2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Illumina Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- QIAGEN NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BGI Genomics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PerkinElmer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bio-Rad Laboratories Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation (Cepheid, IDT)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Oxford Nanopore Technologies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pacific Biosciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eurofins Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GE HealthCare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
